Pharma Research

Modalis and JCR Pharmaceuticals enter into joint research agreement

Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883)  announced that it has entered into a joint research agreement with JCR Pharma...

 December 14, 2023 | News

Illumina and HaploX Collaborate on Benchtop Sequencing System

This marks a new stage in the strategic partnership between the two companies. In the future, Illumina and HaploX will take the localized manufacturing of ...

 December 13, 2023 | News

IQVIA Experts Share Perspectives on Challenges, Opportunities, and the Transformative Role of DCTs in Asia Pacific

In a dynamically evolving landscape of clinical research, the Asia Pacific (APAC) region has emerged as a key player in adopting Decentralized Clinical Tri...

 December 13, 2023 | News

Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics

Lycia is using its proprietary lysosomal targeting chimeras (LYTACs) platform to discover and develop first-in-class therapeutics that degrade extracellula...

 December 05, 2023 | News

XtalPi and HKU's Biomedical Instrumentation Centre Partner to Boost Deep Tech Commercialization

XtalPi, a leading global technology company, is renowned for its expertise in integrating physics-based computation, artificial intelligence (AI), and robo...

 November 28, 2023 | News

PharmAbcine Reveals PMC-403 Potential in Idiopathic Systemic Capillary Leak Syndrome Models

The results underscore the novel mechanism of action, demonstrating the ability of PMC-403 to reduce vascular leakage associated with ISCLS in the preclini...

 November 23, 2023 | News

Taiwan Lubricate for academic research and health products development

In the collaboration with Lipotype GmbH, Germany (the world leader in lipidomics profiling service), T-BAL has developed advanced multi-omics (ma...

 November 20, 2023 | News

ACROBiosystems Introduces GM-Grade DLL4 Protein for Faster Stem Cell Manufacturing

The availability of DLL4 manufactured under GMP conditions represents a significant milestone for enterprises engaged in developing or manufacturing stem-c...

 November 17, 2023 | News

Groundbreaking milestone as the United Kingdom MHRA greenlights CASGEVY™, heralding a new era in CRISPR-based gene editing therapies

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) have shattered scientific barriers today as the United Kingdom Me...

 November 17, 2023 | News

Telix, an Australian Company, Announces Planned Acquisition of QSAM Biosciences and its Lead Therapy Candidate, CycloSam

CycloSam® is highly synergistic with Telix's existing therapeutic development activity in both prostate cancer and sarcoma. The proposed acquisiti...

 November 14, 2023 | News

DiscGenics Collaborates with U.S. Department of Veterans Affairs on Tissue-Engineered Discs

DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate p...

 November 10, 2023 | News

Tempus Collaborates with Bristol Myers Squibb on Multimodal AI Research

"We are looking forward to expanding our relationship with Bristol Myers Squibb and furthering our shared commitment to advancing cancer research and treat...

 November 09, 2023 | News

Bayer and Broad Institute of MIT and Harvard Extend Research Collaboration to Develop New Cancer Therapies

Agreement to focus on joint cancer target identification and discovery of new therapeutic approaches Extended collaboration strengthens Bayer's precisio...

 November 03, 2023 | News

CStone Partners with 3SBio for Nofazinlimab in China

CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and commercialization of nofazinlimab (anti-PD-1 antibody) in ma...

 November 02, 2023 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close